

EXHIBIT A

Teva's Summary Chart Pursuant to the Court's August 4, 2025 Order (Dkt. 121)

Theory of Antitrust Liability	Start of Limitations Period by Statute of Limitations Theory	End of Limitations Period by Statute of Limitations Theory
Exclusive Dealing	<ul style="list-style-type: none"> • April 2024 (“Continuing Violations” doctrine, based on Defendants’ amendments to their exclusive dealing agreement) • May 2024 (“Continuing Violations” doctrine, based on Defendants’ enforcement of their exclusive dealing agreement against Teva) • June 2024 (“Continuing Violations” doctrine, based on Defendants’ steering of prescriptions to Optime pursuant to their exclusive dealing agreement) • August 2020 (“Speculative Damages” doctrine, based on Teva’s receipt of FDA approval) • January 2024 (“Speculative Damages” doctrine, based on Teva’s entry into the market) • August 2020 (Accrual of cause of action based on Teva’s receipt of FDA approval) 	<ul style="list-style-type: none"> • April 2028 (“Continuing Violations” doctrine, based on Defendants’ amendments to their exclusive dealing agreement) • May 2028 (“Continuing Violations” doctrine, based on Defendants’ enforcement of their exclusive dealing agreement against Teva) • June 2028 (“Continuing Violations” doctrine, based on Defendants’ steering of prescriptions to Optime pursuant to their exclusive dealing agreement) • August 2024 (“Speculative Damages” doctrine, based on Teva’s receipt of FDA approval) • January 2028 (“Speculative Damages” doctrine, based on Teva’s entry into the market) • August 2024 (Accrual of cause of action based on Teva’s receipt of FDA approval)
Orange Book Fraud	<ul style="list-style-type: none"> • March 2023 (“Continuing Violations” doctrine, based on Corcept’s assertion of ‘800 and ‘801 patents) • April 2024 (“Continuing Violations” doctrine, based on Defendants’ amendments to their 	<ul style="list-style-type: none"> • March 2027 (“Continuing Violations” doctrine, based on Corcept’s assertion of ‘800 and ‘801 patents) • April 2028 (“Continuing Violations” doctrine, based on Defendants’ amendments to their

Theory of Antitrust Liability	Start of Limitations Period by Statute of Limitations Theory	End of Limitations Period by Statute of Limitations Theory
	<p>exclusive dealing agreement)</p> <ul style="list-style-type: none"> • May 2024 (“Continuing Violations” doctrine, based on Defendants’ enforcement of their exclusive dealing agreement against Teva) • June 2024 (“Continuing Violations” doctrine, based on Defendants’ steering of prescriptions to Optime pursuant to their exclusive dealing agreement) • August 2020 (“Speculative Damages” doctrine, based on Teva’s receipt of FDA approval) • January 2024 (“Speculative Damages” doctrine, based on Teva’s entry into the market) • August 2020 (Accrual of cause of action based on Teva’s receipt of FDA approval) 	<p>exclusive dealing agreement)</p> <ul style="list-style-type: none"> • May 2028 (“Continuing Violations” doctrine, based on Defendants’ enforcement of their exclusive dealing agreement against Teva) • June 2028 (“Continuing Violations” doctrine, based on Defendants’ steering of prescriptions to Optime pursuant to their exclusive dealing agreement) • August 2024 (“Speculative Damages” doctrine, based on Teva’s receipt of FDA approval) • January 2028 (“Speculative Damages” doctrine, based on Teva’s entry into the market) • August 2024 (Accrual of cause of action based on Teva’s receipt of FDA approval)
Sham Patent Litigation	<ul style="list-style-type: none"> • March 2023 (“Continuing Violations” doctrine, based on Corcept’s assertion of ‘800 and ‘801 patents) • April 2024 (“Continuing Violations” doctrine, based on Defendants’ amendments to their exclusive dealing agreement) • May 2024 (“Continuing Violations” doctrine, based on Defendants’ enforcement of their exclusive dealing agreement) 	<ul style="list-style-type: none"> • March 2027 (“Continuing Violations” doctrine, based on Corcept’s assertion of ‘800 and ‘801 patents) • April 2028 (“Continuing Violations” doctrine, based on Defendants’ amendments to their exclusive dealing agreement) • May 2028 (“Continuing Violations” doctrine, based on Defendants’ enforcement of their exclusive dealing agreement)

Theory of Antitrust Liability	Start of Limitations Period by Statute of Limitations Theory	End of Limitations Period by Statute of Limitations Theory
	<p>against Teva)</p> <ul style="list-style-type: none"> • June 2024 (“Continuing Violations” doctrine, based on Defendants’ steering of prescriptions to Optime pursuant to their exclusive dealing agreement) • August 2020 (“Speculative Damages” doctrine, based on Teva’s receipt of FDA approval) • January 2024 (“Speculative Damages” doctrine, based on Teva’s entry into the market) • August 2020 (Accrual of cause of action based on Teva’s receipt of FDA approval) 	<p>against Teva)</p> <ul style="list-style-type: none"> • June 2028 (“Continuing Violations” doctrine, based on Defendants’ steering of prescriptions to Optime pursuant to their exclusive dealing agreement) • August 2024 (“Speculative Damages” doctrine, based on Teva’s receipt of FDA approval) • January 2028 (“Speculative Damages” doctrine, based on Teva’s entry into the market) • August 2024 (Accrual of cause of action based on Teva’s receipt of FDA approval)
Illicit Physician Payments	<ul style="list-style-type: none"> • June 2024 (“Continuing Violations” doctrine, based on Corcept’s continued illicit payments to physicians) • August 2020 (“Speculative Damages” doctrine, based on Teva’s receipt of FDA approval) • January 2024 (“Speculative Damages” doctrine, based on Teva’s entry into the market) • August 2020 (Accrual of cause of action based on Teva’s receipt of FDA approval) 	<ul style="list-style-type: none"> • June 2028 (“Continuing Violations” doctrine, based on Corcept’s continued illicit payments to physicians) • August 2024 (“Speculative Damages” doctrine, based on Teva’s receipt of FDA approval) • January 2028 (“Speculative Damages” doctrine, based on Teva’s entry into the market) • August 2024 (Accrual of cause of action based on Teva’s receipt of FDA approval)